Overview

A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients

Status:
Not yet recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV Trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in Mild Cognitive Impairment Patients with Cerebrovascular Disease

Phase:

Phase 4

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Collaborator:

Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)

Treatments:

Choline